• Daré Bioscience received a new NIH NICHD award of about USD 908,000 to advance its DARE-PTB2 preterm-birth prevention program.
• The notice also recommends about USD 1.3 million in future-year support for initial preclinical pharmacokinetic, safety, and toxicity studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608310844PRIMZONEFULLFEED9818210) on August 31, 2026, and is solely responsible for the information contained therein.